Logo
x

Search

Subscribe Now

aged

Regeneron and Sanofi Report the US FDA's Acceptance of sBLA for Review of Dupixent to Treat Moderate-to-Severe Asthma in Children

Regeneron and Sanofi Report the US FDA's Acceptance of sBLA for Review of Dupixent to Treat Moderate-to-Severe Asthma in Children

  • March 4, 2021
Vertex's Kaftrio + Ivacaftor Receive the EC's Approval to Treat Cystic Fibrosis in People Aged 12 Years and Older

Vertex's Kaftrio + Ivacaftor Receive the EC's Approval to Treat Cystic Fibrosis in People Aged 12 Years and Older

  • August 24, 2020
Astellas' VESIcare LS (solifenacin succinate) Receives the US FDA's Approval to Treat Neurogenic Detrusor Overactivity (Ndo) In Pediatric Patients Aged 2 Years and Older

Astellas' VESIcare LS (solifenacin succinate) Receives the US FDA's Approval to Treat Neurogenic Detrusor Overactivity (Ndo) In Pe...

  • May 27, 2020
Merck & Co's Dificid (fidaxomicin) Receives FDA's Approval to Treat Clostridioides difficile in Children Aged Six Months and Older

Merck & Co's Dificid (fidaxomicin) Receives FDA's Approval to Treat Clostridioides difficile in Children Aged Six Months and Older

  • January 27, 2020
Vertex's Kalydeco (ivacaftor) Receives EC's Approval for Infants with Cystic Fibrosis with CFTR Gene Mutation Aged 6 to

Vertex's Kalydeco (ivacaftor) Receives EC's Approval for Infants with Cystic Fibrosis with CFTR Gene Mutation Aged 6 to

  • December 11, 2019
Biogen's Spinraza (nusinersen) Receives NMPA (CFDA) Approval for Spinal Muscular Atrophy (SMA) Aged 6wks.

Biogen's Spinraza (nusinersen) Receives NMPA (CFDA) Approval for Spinal Muscular Atrophy (SMA) Aged 6wks.

  • March 1, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.